high-dos melphalan autolog bone marrow transplant poor-risk neuroblastoma long-term result patient neuroblastoma month age remiss stage IV diseas refractori diseas patient total bodi irradi cgi autolog bone marrow transplant abmt marrow ex micrograms/ml ascorb micrograms/ml median time absolut neutrophil count day self-sustain platelet day patient infus unpurg reserv marrow group patient underw abmt patient group first remiss median month diagnosi patient group II refractori diseas second remiss group event-fre surviv month month post-abmt group II patient diseas abmt-rel toxic overal patient long-term relapse-fre survivor die abmt-rel toxic patient tumor abmt progress diseas month abmt patient measur diseas abmt month median post-abmt latter relaps primari site site result accord long-term outcom seri neuroblastoma high-dos melphalan residu diseas patient refractori tumor addit pattern relaps sever patient infus autograft recent laboratori evid suboptim purg method 